Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax
Accordingly, we can start the Phase I/II combo-study very soon.
- Accordingly, we can start the Phase I/II combo-study very soon.
- The aim for conducting this study is to judge if DFP-10917 combined with VTX is to show superiority to the standard chemotherapy (azacitidine combined with VTX) for AML.
- This combo-study shall be done by major clinical sites in US like Wake Forest University, expertise with clinical study of novel chemotherapy for AML.
- Please take notice of our own innovative approach for miserable cancer patients and contact with us.